Astellas Pharma Inc. revised consolidated earnings guidance for the year ending March 31, 2024. For the year, the company now expects revenue of JPY 1,562,000 million, operating profit of JPY 13,000 million and profit for the year and profit attributable to owners of the parent of JPY 3,000 million or JPY 1.67 per basic share against previous forecast of revenue of JPY 1,562,000 million, operating profit of JPY 83,000 million and profit for the year and profit attributable to owners of the parent of JPY 58,000 million or JPY 32.34 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,657 JPY | -0.30% | +2.51% | -1.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.72% | 18.82B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024